Yahoo Finance

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement ...

NEW HAVEN, Conn., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Yahoo Finance

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Hosted on MSN

Arvinas Unveils Promising Preclinical Data for ARV-806

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Arvinas Holding Company ( (ARVN)) has ...
Nasdaq

Arvinas, Inc. to Present Preclinical Data for ARV-393 at AACR Annual Meeting 2025

Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...
Hosted on MSN

Arvinas presents preclinical data for ARV-806

Arvinas (ARVN) announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, ...
Nasdaq

Arvinas, Inc. Reports Promising Preclinical Results for ARV-393 in Combination Therapies for Non-Hodgkin Lymphoma

Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...